Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer-Reference-Cited by-同舟云学术

Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer

Published:1999-02 Issue:2 Volume:72 Page:148-153
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Burger Robert A.,DiSaia Philip J.,Roberts James A.,O'Rourke Mark,Gershenson David M.,Homesley Howard D.,Lichtman Stuart M.,Barnes Willard,Moore David H.,Monk Bradley J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference25 articles.

1. Cancer statistics, 1995;Wingo;CA Cancer J Clin,1995

2. Epithelial Ovarian Cancer;DiSaia,1993

3. Experimental antitumor activity of Navelbine;Cros;Semin Oncol,1989

4. Safety and tolerance of Navelbine in phase I–II clinical studies;Besenval;Semin Oncol,1989

5. Vinorelbine (Navelbine): a third-generation vinca alkaloid;Budman;Cancer Invest,1997

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer;Medicine;2023-03-17

2. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models;Therapeutic Advances in Medical Oncology;2023-01

3. Chemotherapeutic Protocols for the Treatment of Gynecological Cancer;Chemotherapy Protocols and Infusion Sequence;2022

4. Overview of Ovarian Cancer Chemotherapy;Advances in Diagnosis and Management of Ovarian Cancer;2022

5. Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents;British Journal of Cancer;2021-05-12